CR and ORR for B-cell ALL and T-cell ALL/LL cohorts
| Response, n (%) [90% CI∗] . | Childhood B-cell ALL (n = 7) . | Childhood T-cell ALL (n = 24) . | Young adult T-cell ALL (n = 5) . | Pooled T-cell ALL (n = 29) . | T-cell LL (n = 10) . |
|---|---|---|---|---|---|
| End of cycle 1 | |||||
| CR | — | 10 (41.7) [24.6-60.3] | 3 (60.0) [18.9-92.4] | — | 3 (30.0) [8.7-60.7] |
| CRi/PR† | — | 4 (16.7) [5.9-34.2] | 1 (20.0) [1.0-65.7] | — | 2 (20.0) [3.7-50.7] |
| Stable disease† | — | — | — | — | 3 (30.0) [8.7-60.7] |
| Refractory ALL | — | 8 (33.3) [17.8-52.1] | 1 (20.0) [1.0-65.7] | — | — |
| Progressive disease | — | 0 | 0 | — | 2 (20.0) [3.7-50.7] |
| Not evaluable | — | 0 | 0 | — | 0 |
| Assessment not performed | — | 2 (8.3) [1.5-24.0] | 0 | — | 0 |
| Any time up to the end of cycle 2 | |||||
| ORR | 1 (14.3) [0.7-52.1] | 20 (83.3) [65.8-94.1] | 4 (80.0) [34.3-99.0] | 24 (82.8) [67.1-93.0] | 5 (50.0) [22.2-77.8] |
| CR | 0 | 12 (50.0) [31.9-68.1] | 3 (60.0) [18.9-92.4] | 15 (51.7) [35.2-68.0] | 4 (40.0) [15.0-69.7] |
| CRi/PR† | 1 (14.3) [0.7-52.1] | 8 (33.3) [17.8-52.1] | 1 (20.0) [1.0-65.7] | 9 (31.0) [17.3-47.9] | 1 (10.0) [0.5-39.4] |
| Stable disease† | — | — | — | — | 3 (30.0) [8.7-60.7] |
| Refractory ALL | 3 (42.9) [12.9-77.5] | 2 (8.3) [1.5-24.0] | 1 (20.0) [1.0-65.7] | 3 (10.3) [2.9-24.6] | — |
| Progressive disease | 3 (42.9) [12.9-77.5] | 0 | 0 | 0 | 2 (20.0) [3.7-50.7] |
| Not evaluable | 0 | 0 | 0 | 0 | 0 |
| Assessment not performed | 0 | 2 (8.3) [1.5-24.0] | 0 | 2 (6.9) [1.2-20.2] | 0 |
| Response, n (%) [90% CI∗] . | Childhood B-cell ALL (n = 7) . | Childhood T-cell ALL (n = 24) . | Young adult T-cell ALL (n = 5) . | Pooled T-cell ALL (n = 29) . | T-cell LL (n = 10) . |
|---|---|---|---|---|---|
| End of cycle 1 | |||||
| CR | — | 10 (41.7) [24.6-60.3] | 3 (60.0) [18.9-92.4] | — | 3 (30.0) [8.7-60.7] |
| CRi/PR† | — | 4 (16.7) [5.9-34.2] | 1 (20.0) [1.0-65.7] | — | 2 (20.0) [3.7-50.7] |
| Stable disease† | — | — | — | — | 3 (30.0) [8.7-60.7] |
| Refractory ALL | — | 8 (33.3) [17.8-52.1] | 1 (20.0) [1.0-65.7] | — | — |
| Progressive disease | — | 0 | 0 | — | 2 (20.0) [3.7-50.7] |
| Not evaluable | — | 0 | 0 | — | 0 |
| Assessment not performed | — | 2 (8.3) [1.5-24.0] | 0 | — | 0 |
| Any time up to the end of cycle 2 | |||||
| ORR | 1 (14.3) [0.7-52.1] | 20 (83.3) [65.8-94.1] | 4 (80.0) [34.3-99.0] | 24 (82.8) [67.1-93.0] | 5 (50.0) [22.2-77.8] |
| CR | 0 | 12 (50.0) [31.9-68.1] | 3 (60.0) [18.9-92.4] | 15 (51.7) [35.2-68.0] | 4 (40.0) [15.0-69.7] |
| CRi/PR† | 1 (14.3) [0.7-52.1] | 8 (33.3) [17.8-52.1] | 1 (20.0) [1.0-65.7] | 9 (31.0) [17.3-47.9] | 1 (10.0) [0.5-39.4] |
| Stable disease† | — | — | — | — | 3 (30.0) [8.7-60.7] |
| Refractory ALL | 3 (42.9) [12.9-77.5] | 2 (8.3) [1.5-24.0] | 1 (20.0) [1.0-65.7] | 3 (10.3) [2.9-24.6] | — |
| Progressive disease | 3 (42.9) [12.9-77.5] | 0 | 0 | 0 | 2 (20.0) [3.7-50.7] |
| Not evaluable | 0 | 0 | 0 | 0 | 0 |
| Assessment not performed | 0 | 2 (8.3) [1.5-24.0] | 0 | 2 (6.9) [1.2-20.2] | 0 |